UBS Gives Zai Lab (ZLAB) a Buy Rating [Yahoo! Finance]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Yahoo! Finance
on Zai Lab Limited (NASDAQ:ZLAB), giving the stock a Buy rating and setting the price target at $35. The research firm noted that the company is moving beyond its previous focus on China to become a global innovation leader. UBS sees Zai Lab Limited (NASDAQ:ZLAB) as undervalued and pointed out that the market is not fully recognizing the value of its global pipeline, which improves its strategic positioning, diversifies revenue streams, and creates potential long-term value for shareholders. The firm also noted that this pipeline is shifting towards high-value, innovative treatments aimed at significant unmet needs. According to UBS, this could significantly shape Zai Lab Limited's (NASDAQ:ZLAB) growth over the next decade. In other news, on January 6, Zai Lab Limited (NASDAQ:ZLAB) reported that the National Medical Products Administration (NMPA) in China has approved the supplemental New Drug Application (sNDA) for AUGTYRO (repotrectinib). The drug is approved for adult patient
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Zai Lab (NASDAQ:ZLAB) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
- Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors [Yahoo! Finance]Yahoo! Finance
ZLAB
Earnings
- 11/6/25 - Miss
ZLAB
Sec Filings
- 1/2/26 - Form 4
- 12/31/25 - Form 144
- 12/18/25 - Form 4
- ZLAB's page on the SEC website